Inclusion Criteria:  Ages 16-65 years inclusive. Ability to comprehend the investigational nature of the study and provide informed consent. Expected survival time ≥ 3 months (according to investigator's judgement) Acute leukemia in complete remission diagnosed with alloimmune-mediated PTR, characterized by all of the following:  Lack of adequate post-transfusion platelet count increment, defined by CCI <7500/μl at 10-60 min, and CCI <5000/μl at 18-24 hrs (in those who had a CCI at 10-60 min greater than or equal to 5000/μl) after at least 2 consecutive transfusions.  Presence of anti-HLA class A and/or B antibody.  Left ventricular ejection fractions ≥ 0.5 by echocardiography. Creatinine < 1.6 mg/dL. Aspartate aminotransferase/aspartate aminotransferase < 3x upper limit of normal. Total bilirubin <2.0 mg/dL. karnofsky performance status ≥ 60.  Exclusion Criteria:  PTR induced by other reasons(eg:DIC,fever,infection and splenomegaly) Uncontrolled active infection. Active hepatitis B or hepatitis C infection Patients with HIV or syphilis infection Patients are pregnant or lactating Patients has a history of allo-HSCT Alloimmune-mediated PTR responsive to treatment with plasma exchange Alloimmune-mediated PTR responsive to treatment with rituximab or IVIG Grade III/IV cardiovascular disability according to the New York Heart Association Classification Patients with other contraindications considered unsuitable for participation in this study (according to investigator's judgement)